ArticleCell communication and signaling : CCS2026
Tuberous sclerosis complex 2 association with RelA/p65 is critical for NF-κB activation and endothelial cell inflammation.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEndothelial cell (EC) inflammation is a key component of many inflammatory conditions including sepsis and acute lung injury (ALI). However, the role of Tuberous Sclerosis Complex 2 (TSC2) in activating NF-κB and inflammatory response in EC has not been addressed.
methodsHuman pulmonary artery endothelial cells (HPAEC) or human lung microvascular endothelial cells (HLMVEC) were transfected with siRNA targeting TSC2 and then challenged with thrombin, a procoagulant and proinflammatory mediator whose concentration is elevated in patients with ALI and sepsis, to address the role of TSC2 in activating NF-κB subunit RelA/p65 to cause inflammatory response in EC. In some experiments, lipopolysaccharide (LPS), a robust inducer of EC inflammation, was used to determine if TSC2 is common mediator of this response. The cells were evaluated for IκBα phosphorylation/degradation, RelA/p65 phosphorylation and nuclear accumulation by immunoblotting. DNA binding of nuclear RelA/p65 was determined using an ELISA-based assay kit. RelA/p65 transcriptional activity was determined by measuring NF-κB-luciferase reporter activity. TSC2 association with RelA/p65 was assessed by immunoprecipitation followed by immunoblotting.
resultsWe found that RelA/p65 is constitutively associated with TSC2 (in addition to IκBα), and this association is reduced in thrombin-stimulated cells, suggesting a role of TSC2 in regulating RelA/p65 activation and EC inflammatory response. We examined this possibility by silencing TSC2 to disrupt its association with RelA/p65-IκBα complex. TSC2 silencing resulted in reduced IκBα phosphorylation/degradation, and subsequently, RelA/p65 nuclear translocation and DNA binding activity in response to thrombin. TSC2-silenced cells also showed reduced Ser
conclusionsTogether, these results identify TSC2 as a critical component of RelA/p65-IκBα complex that aids in facilitating the activation of RelA/p65 to cause EC inflammatory response. Thus, the targeting of TSC2 may be a useful strategy for mitigating EC inflammation associated with intravascular coagulation and sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.